ニュース

Beida Pharmaceuticals Divests API Business, Aims to Turn Losses into Profit for the Year

[Beida Pharmaceuticals overall divestment of API business and strive to turn losses into profits throughout the year] Beida Pharmaceuticals November 6 board of directors decided, to be held in an agreement involving the API business subsidiaries Daxin Pharmaceuticals 92.26% of the shares, Chongqing Synthesis 100% of the equity, Fangxin Chemical 66.86% of the equity and 100% of the equity of Chongqing and Sheng transferred to the controlling shareholder of the Southwest Synthesis Pharmaceuticals Group and its wholly owned subsidiaries, the total valuation of about 766 million yuan. The total valuation is about 766 million yuan. Through this major asset reorganization, the listed company will lose a large loss of API business related subsidiaries transferred to the outside world, is conducive to reducing losses and improve profitability.

2015

11-13

Chemical API production wastewater treatment difficulties?

[China Pharmaceutical Network Editor's View] I China's pharmaceutical industry is divided into chemical drug raw materials manufacturing, chemical drug preparation manufacturing, processing of traditional Chinese medicine tablets, the production of proprietary Chinese medicines, veterinary drug manufacturing, biological drug manufacturing and sanitary materials and medical supplies manufacturing seven sub-industries.

2015

11-13

Health Yuan's integration of Lizhu Group aborted again What will happen to the raw material drug assets?

Two months ago, hope that through the divestiture of pharmaceutical assets to achieve asset integration of health yuan (600380.SH), in the evening of October 27 announced the termination of the major asset integration plan, the reason is that "the two sides in the transaction price and other matters there is a big difference, it is expected to be difficult to reach agreement in the short term".

2015

11-13

Low-priced drugs are unprofitable and abandoned, and raw materials are monopolized.

[China Pharmaceutical Industry News] cheap and cheap should be welcomed by the market and consumers, however, the reporter investigated and found that at the critical moment, some of the life-saving cheap and good drugs in reality has become a "lone drug". Commonly used drugs Pansentin drug shortage is becoming more and more serious. Pansentin, also known as dipyridamole, has the effect of expanding coronary blood vessels, promoting the formation of collateral circulation and mild anticoagulation, antiviral effect, is a commonly used drug for the prevention of thromboembolic disease. However, it is now difficult to find the drug on the market.

2015

11-13

Commonly used drug "Pansentin" is hard to find General medicine raw materials are monopolized

[China Pharmaceutical Network domestic news] In fact, not only Pansentin, bispyrimethamine tablets, fish essence protein, Yin Qiao Chong, Vibramycin Lutong, these people are familiar with the cheap drug is now also a drug hard to find.

2015

11-13

Commonly used drugs Pansentin API is monopolized by the pharmaceutical companies unprofitable to make a drug hard to find

The shortage of commonly used drug Pansentin is getting worse. Pansentin, also known as dipyridamole, has the effect of dilating coronary blood vessels, promoting the formation of collateral circulation and mild anticoagulant effect and antiviral effect, and it is a commonly used drug for the prevention of thromboembolic diseases. However, it is now difficult to find the drug on the market.

2015

11-13

< 12 > ジへ ペー
画像名

オンラインメッセージ

当社の製品に興味があり、詳細を知りたい場合は、ここにメッセージを残してください。できるだけ早く返信します。

提出